LMRI
Lumexa Imaging Holdings, Inc. (NASDAQ)
Healthcare — Medical Devices
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.
Strong Buy
1.3 / 5
7 analysts
$11.59
+$0.31 (+2.75%)
Target:
$17.29
(49.1%)
Sign in to add LMRI to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $1.11B |
| P/E Ratio (TTM) | - |
| Forward P/E | 12.87 |
| EPS (TTM) | $-0.39 |
| Dividend Yield | - |
| Profit Margin | -3.66% |
| Revenue Growth | 3.10% |
| ROE | - |
| Debt/Equity | 161.34 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $17.29 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 71.2 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $19.45 |
| 52-Week Low | $6.45 |
| 50-Day Avg | $9.10 |
| 200-Day Avg | $12.08 |
| Avg Volume | 887.0K |
| Volume | 481.7K |
Performance Analysis
NEUTRALLMRI presents a mixed picture with both positive and negative indicators.
~
Trading at 40% of its 52-week range.
-
RSI at 71.2 indicates overbought conditions — a pullback may be due.
~
Modest revenue growth of 3.1% year-over-year.
-
Operating at a loss with -3.7% margin.
+
Wall Street consensus is "Strong Buy" from 7 analysts.
+
Average analyst target of $17.29 implies 49.1% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:18 UTC
Back to Screener Export Report